Clinical Trial Detail

NCT ID NCT02375958
Title PCA062 in pCAD-positive Tumors.
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

esophageal cancer

triple-receptor negative breast cancer

head and neck squamous cell carcinoma

Therapies

PCA062

Age Groups: adult senior

No variant requirements are available.